Skip to main content
← Back to lionheartlongevity.comRule 506(c) Private Offering
Lionheart LongevityPPM
Menu

Management analysis

Industry Comparables

Lionheart Health, Inc. versus nearest peer companies in the regenerative medicine sector.

Lionheart Health is developing a platform centered on bioelectric stimulation to control protein expression, with applications in regenerative aesthetics, healthspan longevity and bioelectric-enhanced biologics. Its proposed distinction is the ability to modulate regenerative signaling across multiple applications.

The selected peers pursue extracellular-matrix restoration, topical drug delivery, cardiac cell therapies, fibroblast therapies, cardiac-derived cells/exosomes or mesenchymal stem cells. Development stages and evidence differ materially; this comparison does not establish superior efficacy or valuation.

Intellectual property: issued, owned, licensed, optioned and pending

CompanyDisclosed portfolio measureOwnership / licensesOptions / pending / in-process status
Lionheart Health700+ patent claims, reported across issued, pending, licensed, optioned and in-process categories [1]. Claims are not individual patents.Company/Leonhardt Ventures platform relationships; an exclusive Lionheart license for RegenaLung was announced in May 2026 [2].Category-by-category counts and a current rights schedule were not established. Broader team claims of 3,000+ are separate from the 700+ platform figure [3].
Conexeu SciencesPatent estate spanning 40+ jurisdictions; this is not a patent count [4].July 2026 disclosure states outright platform ownership, without royalty or licensing obligations.Canada protection described as pending; issued/application split and option count not disclosed in reviewed material.
Turn TherapeuticsAt Dec. 31, 2025: 16 issued patents (14 U.S., 2 foreign), 12 pending applications (5 U.S., 5 foreign, 2 PCT) [5].Annual report states ownership of the listed portfolio.Pending counts above; separate option/license count not disclosed in reviewed material.
BioCardia70+ issued patents and pending applications worldwide at Dec. 31, 2025 [6].Sole ownership of material patents except exclusive licenses from Biomet Biologics and CART-TECH.Combined total; issued/pending and option splits not provided in the cited summary.
FibroBiologics270+ issued patents and pending applications in U.S./international jurisdictions [7].Company describes its portfolio as held by FibroBiologics.New GLP-1/peptide patent application announced Oct. 7, 2026 [8]; current option/license split not established.
Capricor TherapeuticsAggregate issued/pending count not established in reviewed disclosures.Exclusive cardiac-derived cell IP licenses from University of Rome, Johns Hopkins and Cedars-Sinai; Cedars-Sinai exosome IP license [9].Licensed patent/application schedules and owned developments are not presented here as a verified combined count; options not quantified.
BioRestorative TherapiesAggregate current count not established; BRTX-100 and ThermoStem patent protection disclosed [10].Disc/spine license with Regenerative; underlying licensed patents assigned to Regenexx.ThermoStem Japanese notice of allowance reported Oct. 2025 [11]; allowance is distinct from issuance. Options not quantified.
LongeveronCompany-owned and in-licensed IP; a current aggregate count was not established [12].University of Miami technology license; separately licensed issued U.S. patent 12,168,028 B2 for cardiomyogenic precursor cells [13].Pending applications in Alzheimer's disease and potency-assay families; option count not established.

Clinical studies: completed work and current programs

Counts below are named examples/minimums identified, not comprehensive company trial inventories. A primary readout or enrollment completion does not mean that all follow-up is complete. Team career studies, preclinical experiments, clinical programs and company-sponsored human trials are separate measures.

CompanyCompleted studies / reported clinical workStudies in process / development status
Lionheart HealthManagement reports 12 co-sponsored clinical studies related to the current platform; completion status and study-level inventory remain to be confirmed. Separately reports 500+ studies across core team careers [3]. BodStim clinical results and BodStim/Brain Band data have been announced [14,15].At least 1 named program: Klotho-Up longitudinal healthspan study, enrollment announced March 2026 [16]. Other active-study totals not verified.
Conexeu SciencesCompleted human-trial total not established. Describes itself as preclinical-stage in Aug. 2026 [17].Human-trial initiation not verified; lead Ten-Minute Tissue ECM platform remains investigational/preclinical.
Turn TherapeuticsCompleted company-trial total not established; interim data reported from GX-03. FDA device clearances are not counted as completed clinical trials.At least 1: adaptive Phase 2 GX-03 atopic dermatitis trial; Stage 2 enrollment expected to finish Q4 2026 [18].
BioCardiaAt least 1 company-led pivotal readout: CardiAMP Heart Failure Phase 3, 125 enrolled/115 randomized; primary endpoint not met. Prior TRIDENT/POSEIDON research provides additional supporting experience [19].CardiAMP HF II confirmatory trial advancing as of Oct. 7, 2026 [20]. CardiALLO Phase 1/2 development also disclosed [21]; latest recruitment status not established here.
FibroBiologicsAt least 1: early Phase 0/1 multiple sclerosis feasibility study, 5 participants, 16-week results reported [22].At least 1: CYWC628 Phase 1/2 diabetic-foot-ulcer trial; patients dosed, results expected late 2026. Planned IND submissions are not active clinical studies [7].
Capricor TherapeuticsAt least 1 pivotal primary readout: HOPE-3 Phase 3, 106 participants, results published July 2026 [23]. Prior HOPE-2 work is additional clinical history.HOPE-3 remains listed active, not recruiting; open-label extension results reported [24,25]. Primary readout and extension are not double-counted as separate completed trials.
BioRestorative TherapiesCompleted BRTX-100 Phase 2 trial not claimed: enrollment of 99 participants completed Feb. 2026 [26].At least 1: BRTX-100 Phase 2 chronic lumbar disc disease study with follow-up/blinded analyses. ThermoStem remains a separate development program.
LongeveronAt least 3 named primary readouts: ELPIS I, CLEAR MIND Phase 2a and ELPIS II Phase 2b. ELPIS II reported Sept. 16, 2026: 40 infants; primary endpoint not met [27,28].ELPIS II long-term survival follow-up planned up to 5 years. Further HLHS development subject to FDA discussions; current total of recruiting trials not established [28].

Scientific and clinical team experience and publications

CompanyRelevant disclosed experiencePublication measure available
Lionheart HealthManagement dates first bioelectric regeneration case to 1987 and first biologics case to 1988; multidisciplinary team/advisors spanning regeneration, cardiovascular trials, neuroscience and devices [3].8,300+ peer-reviewed publications, management-reported founding/core team career figure [3]. Aggregate requires roster reconciliation and removal of duplicate co-authored papers. It is not a count of Lionheart-sponsored studies or platform-specific papers.
Conexeu SciencesCMO Brian Pilcher: 25+ years in dermatology/aesthetics and 15 clinical programs; CSO Claudia Chavez-Munoz: tissue engineering and regenerative surgery [29].Chavez-Munoz 40+, Pilcher 20+ papers, as individually reported. A unique team total is not disclosed; do not simply add overlapping papers.
Turn TherapeuticsClinical/regulatory leadership includes former FDA Commissioner Stephen Hahn; CSO Robert Redfield brings immunology/infectious-disease expertise [30].Aggregate team career count not disclosed in reviewed sources. A GX-03 preclinical peer-reviewed article was announced May 2026 [31].
BioCardiaCEO Peter Altman has led the company since 2002, with life-science research and product-development experience [32].40 scientific publications, individually attributed to Altman; unique full-team total not disclosed.
FibroBiologicsCSO Hamid Khoja: 25+ years scientific-team leadership and assay/drug-development technologies [33].Khoja 27+ peer-reviewed papers; unique full-team total not disclosed. His 3,000+ methodology citations are citations, not publications.
Capricor TherapeuticsCEO Linda Marban reports 20+ years in biotechnology; company founded around cardiac-derived cell science [34].250+ scientific publications concerning CDCs, a field/technology literature measure [35]. Unique team career total not established; this cannot be ranked against Lionheart's career figure.
BioRestorative TherapiesFrancisco Silva: cell-therapy R&D, prior biologics company leadership and BRT service since 2011; named regenerative medicine journal section editor [36,37].Numerous stem-cell publications reported; numeric unique team total not disclosed.
LongeveronCo-founder/CSO Joshua Hare and University of Miami translational stem-cell work underpin laromestrocel programs [12,38].Company maintains a publication archive [39]; a verified unique career total for the current team was not established.

Interpretation for investors

Lionheart's disclosed strength is its broad bioelectric protein-expression platform and the reported career experience of its scientific and clinical network. BioCardia, Capricor and Longeveron have identifiable later-stage human-trial readouts; FibroBiologics and BioRestorative provide cell-therapy comparators; Conexeu is a closer regenerative-aesthetics platform comparator, while Turn provides a topical delivery/inflammation comparator. Patent claims, patent documents, jurisdictions, publications and study counts are not interchangeable indicators of therapeutic success or economic value.

Sources

  1. 1.Lionheart/Rejuvant announcement, Feb. 6, 2026
  2. 2.RegenaLung patent filing and exclusive license announcement
  3. 3.Howard Leonhardt management statement: team history, publications and studies
  4. 4.Conexeu July 7, 2026 disclosure
  5. 5.Turn 2025 Form 10-K
  6. 6.BioCardia 2025 Form 10-K
  7. 7.FibroBiologics July 31, 2026 update
  8. 8.FibroBiologics Oct. 7, 2026 patent announcement
  9. 9.Capricor 2025 Form 10-K
  10. 10.BioRestorative Feb. 13, 2026 prospectus
  11. 11.BioRestorative ThermoStem Japanese allowance
  12. 12.Longeveron 2025 Form 10-K
  13. 13.Longeveron new University of Miami patent license
  14. 14.BodStim May 3, 2026 results announcement
  15. 15.Lionheart Sept. 2026 BodStim/Brain Band presentation
  16. 16.Klotho-Up enrollment announcement, Mar. 27, 2026
  17. 17.Conexeu Aug. 11, 2026 company announcement
  18. 18.Turn July 7, 2026 Phase 2 update
  19. 19.BioCardia CardiAMP Phase 3 report
  20. 20.BioCardia Oct. 7, 2026 HF II update
  21. 21.BioCardia CardiALLO Phase 1/2 update
  22. 22.FibroBiologics five-patient MS study poster
  23. 23.Capricor HOPE-3 publication announcement, July 29, 2026
  24. 24.Capricor clinical trial status
  25. 25.Capricor HOPE-3 extension data
  26. 26.BioRestorative 2025 Form 10-K, filed Mar. 26, 2026
  27. 27.Longeveron Q2 2025 update: ELPIS I and CLEAR MIND
  28. 28.Longeveron ELPIS II results, Sept. 16, 2026
  29. 29.Conexeu leadership biographies
  30. 30.Turn appoints CSO Robert Redfield, Sept. 9, 2026
  31. 31.Turn Q2 2026 update and publication announcement
  32. 32.BioCardia Peter Altman biography
  33. 33.FibroBiologics Hamid Khoja biography
  34. 34.Capricor leadership
  35. 35.Capricor CDC science literature
  36. 36.BioRestorative Francisco Silva biography
  37. 37.BioRestorative Silva journal appointment
  38. 38.Longeveron co-founder/CSO research background
  39. 39.Longeveron publications archive